OBJECTIVES: To examine the effect of specific cerebrospinal fluid (CSF) profiles on the rate of cognitive decline, disease progression, and risk of conversion to Alzheimer disease (AD) dementia in patients with amnestic mild cognitive impairment (MCI). DESIGN: Total tau (T-tau), tau phosphorylated at threonine 181, and β-amyloid 1-42 peptide (Aβ42) were immunoassayed in CSF samples obtained from patients with MCI enrolled in the Alzheimer's Disease Neuroimaging Initiative. Patients were then stratified by CSF profiles: (1) normal T-tau and normal Aβ42 (ie, normal-T-tauAβ42), (2) normal T-tau but abnormal Aβ42 (ie, abnormal-Aβ42), (3) abnormal T-tau but normal Aβ42 (ie, abnormal-T-tau), and (4) abnormal T-tau and abnormal Aβ42 (ie, abnormal-T-tauAβ42). SETTING: Fifty-eight sites in the United States and Canada. PARTICIPANTS: One hundred ninety-five patients with MCI. MAIN OUTCOME MEASURES: A composite cognitive measure, the Clinical Dementia Rating Scale-sum of boxes subscale, and conversion to AD dementia. RESULTS: Patients with MCI with a CSF profile of abnormal-Aβ42 or abnormal-T-tauAβ42 experienced a faster rate of decline on the composite cognitive measure and the Clinical Dementia Rating Scale-sum of boxes subscale compared with those with normal-T-tauAβ42. They also had a greater risk of converting to AD dementia relative to the normal-T-tauAβ42 group. In contrast, those with a CSF profile of abnormal-T-tau did not differ from the normal-T-tauAβ42 group on any outcome. These findings were generally replicated when the sample was reclassified by patterns of tau phosphorylated at threonine 181 and Aβ42 abnormalities. CONCLUSIONS: β-Amyloid abnormalities but not tau alterations are associated with cognitive deterioration, disease progression, and increased risk of conversion to AD dementia in patients with MCI. Patients with abnormal Aβ42 may be prime candidates for drug treatment and clinical trials in MCI.
OBJECTIVES: To examine the effect of specific cerebrospinal fluid (CSF) profiles on the rate of cognitive decline, disease progression, and risk of conversion to Alzheimer disease (AD) dementia in patients with amnestic mild cognitive impairment (MCI). DESIGN: Total tau (T-tau), tau phosphorylated at threonine 181, and β-amyloid 1-42 peptide (Aβ42) were immunoassayed in CSF samples obtained from patients with MCI enrolled in the Alzheimer's Disease Neuroimaging Initiative. Patients were then stratified by CSF profiles: (1) normal T-tau and normal Aβ42 (ie, normal-T-tauAβ42), (2) normal T-tau but abnormal Aβ42 (ie, abnormal-Aβ42), (3) abnormal T-tau but normal Aβ42 (ie, abnormal-T-tau), and (4) abnormal T-tau and abnormal Aβ42 (ie, abnormal-T-tauAβ42). SETTING: Fifty-eight sites in the United States and Canada. PARTICIPANTS: One hundred ninety-five patients with MCI. MAIN OUTCOME MEASURES: A composite cognitive measure, the Clinical Dementia Rating Scale-sum of boxes subscale, and conversion to AD dementia. RESULTS:Patients with MCI with a CSF profile of abnormal-Aβ42 or abnormal-T-tauAβ42 experienced a faster rate of decline on the composite cognitive measure and the Clinical Dementia Rating Scale-sum of boxes subscale compared with those with normal-T-tauAβ42. They also had a greater risk of converting to AD dementia relative to the normal-T-tauAβ42 group. In contrast, those with a CSF profile of abnormal-T-tau did not differ from the normal-T-tauAβ42 group on any outcome. These findings were generally replicated when the sample was reclassified by patterns of tau phosphorylated at threonine 181 and Aβ42 abnormalities. CONCLUSIONS: β-Amyloid abnormalities but not tau alterations are associated with cognitive deterioration, disease progression, and increased risk of conversion to AD dementia in patients with MCI. Patients with abnormal Aβ42 may be prime candidates for drug treatment and clinical trials in MCI.
Authors: D I Kaufer; J L Cummings; P Ketchel; V Smith; A MacMillan; T Shelley; O L Lopez; S T DeKosky Journal: J Neuropsychiatry Clin Neurosci Date: 2000 Impact factor: 2.198
Authors: Ozioma C Okonkwo; Michael L Alosco; H Randall Griffith; Michelle M Mielke; Leslie M Shaw; John Q Trojanowski; Geoffrey Tremont Journal: Arch Neurol Date: 2010-06
Authors: Arto Nordlund; Sindre Rolstad; Ola Klang; Karin Lind; Mona Pedersen; Kaj Blennow; Ake Edman; Stefan Hansen; Anders Wallin Journal: J Int Neuropsychol Soc Date: 2008-07 Impact factor: 2.892
Authors: H Hampel; S J Teipel; T Fuchsberger; N Andreasen; J Wiltfang; M Otto; Y Shen; R Dodel; Y Du; M Farlow; H-J Möller; K Blennow; K Buerger Journal: Mol Psychiatry Date: 2004-07 Impact factor: 15.992
Authors: Shanker Swaminathan; Shannon L Risacher; Karmen K Yoder; John D West; Li Shen; Sungeun Kim; Mark Inlow; Tatiana Foroud; William J Jagust; Robert A Koeppe; Chester A Mathis; Leslie M Shaw; John Q Trojanowski; Holly Soares; Paul S Aisen; Ronald C Petersen; Michael W Weiner; Andrew J Saykin Journal: Alzheimers Dement Date: 2013-03-26 Impact factor: 21.566
Authors: Nicolas R Barthélemy; Yan Li; Nelly Joseph-Mathurin; Brian A Gordon; Jason Hassenstab; Tammie L S Benzinger; Virginia Buckles; Anne M Fagan; Richard J Perrin; Alison M Goate; John C Morris; Celeste M Karch; Chengjie Xiong; Ricardo Allegri; Patricio Chrem Mendez; Sarah B Berman; Takeshi Ikeuchi; Hiroshi Mori; Hiroyuki Shimada; Mikio Shoji; Kazushi Suzuki; James Noble; Martin Farlow; Jasmeer Chhatwal; Neill R Graff-Radford; Stephen Salloway; Peter R Schofield; Colin L Masters; Ralph N Martins; Antoinette O'Connor; Nick C Fox; Johannes Levin; Mathias Jucker; Audrey Gabelle; Sylvain Lehmann; Chihiro Sato; Randall J Bateman; Eric McDade Journal: Nat Med Date: 2020-03-11 Impact factor: 53.440
Authors: John M Ringman; Giovanni Coppola; David Elashoff; Yaneth Rodriguez-Agudelo; Luis D Medina; Karen Gylys; Jeffrey L Cummings; Greg M Cole Journal: Dement Geriatr Cogn Disord Date: 2012-02-13 Impact factor: 2.959
Authors: Rodrigo P Almeida; Stephanie A Schultz; Benjamin P Austin; Elizabeth A Boots; N Maritza Dowling; Carey E Gleason; Barbara B Bendlin; Mark A Sager; Bruce P Hermann; Henrik Zetterberg; Cynthia M Carlsson; Sterling C Johnson; Sanjay Asthana; Ozioma C Okonkwo Journal: JAMA Neurol Date: 2015-06 Impact factor: 18.302
Authors: Craig Ritchie; Nadja Smailagic; Anna H Noel-Storr; Obioha Ukoumunne; Emma C Ladds; Steven Martin Journal: Cochrane Database Syst Rev Date: 2017-03-22
Authors: Beau M Ances; Tammie L Benzinger; Jon J Christensen; Jewell Thomas; Rohit Venkat; Mengesha Teshome; Patricia Aldea; Anne M Fagan; David M Holtzman; John C Morris; David B Clifford Journal: Arch Neurol Date: 2012-01
Authors: Valerie A Cardenas; Duygu Tosun; Linda L Chao; P Thomas Fletcher; Sarang Joshi; Michael W Weiner; Norbert Schuff Journal: J Neuroimaging Date: 2013-02-19 Impact factor: 2.486